

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

ORIAHNN
(elagolix/estradiol/norethindrone acetate)

Status: CVS Caremark® Criteria
Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Oriahnn is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.

Limitation of Use:

Use of Oriahnn should be limited to 24 months due to the risk of continued bone loss, which may not be reversible.

COVERAGE CRITERIA

Heavy Menstrual Bleeding Associated with Uterine Leiomyomas (Fibroids)

Authorization may be granted when the requested drug is being prescribed for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) when ALL of the following criteria are met:

- The patient is premenopausal
- If the patient has previously received treatment with an elagolix-containing product (e.g., Oriahnn, Orilissa) or a relugolix-containing product (e.g., Myfembree), the patient has not already received ANY of the following: Greater than or equal to 24 cumulative months of treatment with elagolix-containing products (e.g., Oriahnn, Orilissa) and/or relugolix-containing products (e.g., Myfembree), Greater than or equal to 6 months of treatment with Orilissa 200 mg twice daily

DURATION OF APPROVAL (DOA)

- 3960-A: Total additive duration: 24 months (see chart)

Cumulative months of prior treatment with an elagolix- and/or relugolix-containing product	Duration of Approval (in months)
No prior treatment	12
≤ 12	12
13	11
14	10
15	9
16	8
17	7
18	6
19	5
20	4
21	3
22	2
23	1

Oriahnn PA Policy UDR 01-2024.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

REFERENCES

1. Myfembree [package insert]. Brisbane, CA: Myovant Sciences, Inc.; August 2023.
2. Oriahnn [package insert]. North Chicago, IL: AbbVie Inc.; June 2023.
3. Orilissa [package insert]. North Chicago, IL: AbbVie Inc.; June 2023.
4. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed December 06, 2023.
5. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 12/06/2023).